SAN

77.66

-4.48%↓

SHL.DE

40.47

-0.27%↓

ACB

3.45

-3.36%↓

SAN

77.66

-4.48%↓

SHL.DE

40.47

-0.27%↓

ACB

3.45

-3.36%↓

SAN

77.66

-4.48%↓

SHL.DE

40.47

-0.27%↓

ACB

3.45

-3.36%↓

SAN

77.66

-4.48%↓

SHL.DE

40.47

-0.27%↓

ACB

3.45

-3.36%↓

SAN

77.66

-4.48%↓

SHL.DE

40.47

-0.27%↓

ACB

3.45

-3.36%↓

Search

Almirall SA

Abrir

SetorSaúde

13.42

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.4

Máximo

13.66

Indicadores-chave

By Trading Economics

Rendimento

13M

21M

Vendas

-14M

260M

P/E

Médio do Setor

60.7

121.746

EPS

0.1

Margem de lucro

8.059

Funcionários

2,026

EBITDA

12M

66M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+5.42% upside

Dividendos

By Dow Jones

Próximos Ganhos

23 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-80M

2.6B

Abertura anterior

13.42

Fecho anterior

13.42

Sentimento de Notícias

By Acuity

14%

86%

11 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Almirall SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de fev. de 2026, 23:47 UTC

Ações em Alta

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 de fev. de 2026, 22:59 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Grab Holdings to Buy U.S.-Based Stash Financial

11 de fev. de 2026, 23:54 UTC

Ganhos

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 de fev. de 2026, 23:49 UTC

Ganhos

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 de fev. de 2026, 23:45 UTC

Ganhos

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 de fev. de 2026, 23:42 UTC

Ganhos

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 de fev. de 2026, 23:41 UTC

Ganhos

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 de fev. de 2026, 23:40 UTC

Ganhos

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 de fev. de 2026, 23:35 UTC

Conversa de Mercado

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 de fev. de 2026, 23:18 UTC

Conversa de Mercado

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 de fev. de 2026, 23:14 UTC

Conversa de Mercado

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 de fev. de 2026, 22:58 UTC

Ganhos

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 de fev. de 2026, 22:57 UTC

Ganhos

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 de fev. de 2026, 22:54 UTC

Ganhos

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 de fev. de 2026, 22:53 UTC

Ganhos

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:23 UTC

Ganhos

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 de fev. de 2026, 22:19 UTC

Ganhos

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 de fev. de 2026, 22:16 UTC

Ganhos

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparação entre Pares

Variação de preço

Almirall SA Previsão

Preço-alvo

By TipRanks

5.42% parte superior

Previsão para 12 meses

Média 14 EUR  5.42%

Máximo 14 EUR

Mínimo 14 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Almirall SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

9.76 / 10.2Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Sentimento

By Acuity

11 / 352 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat